Trial Profile
A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs SYN 023 (Primary) ; Rabies immune globulin; Rabies immune globulin; Rabies vaccine
- Indications Rabies
- Focus Pharmacodynamics
- Acronyms ARPEP
- Sponsors Synermore Biologics
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 03 May 2022 Planned End Date changed from 31 May 2022 to 31 Aug 2022.
- 03 May 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Jun 2022.